sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks 4-Butylresorcinol

4-Butylresorcinol

CAS No.:
18979-61-8
Catalog Number:
AG002DZ4
Molecular Formula:
C10H14O2
Molecular Weight:
166.2170
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
250mg
98%(GC)
In Stock USA
United States
$129
- +
1g
98%(GC)
In Stock USA
United States
$422
- +
5g
98%(GC)
In Stock USA
United States
$1228
- +
Product Description
Catalog Number:
AG002DZ4
Chemical Name:
4-Butylresorcinol
CAS Number:
18979-61-8
Molecular Formula:
C10H14O2
Molecular Weight:
166.2170
MDL Number:
MFCD01684800
IUPAC Name:
4-butylbenzene-1,3-diol
InChI:
InChI=1S/C10H14O2/c1-2-3-4-8-5-6-9(11)7-10(8)12/h5-7,11-12H,2-4H2,1H3
InChI Key:
CSHZYWUPJWVTMQ-UHFFFAOYSA-N
SMILES:
CCCCc1ccc(cc1O)O
EC Number:
606-191-2
UNII:
2IK4UQ3ZGA
Properties
Complexity:
125  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
166.099g/mol
Formal Charge:
0
Heavy Atom Count:
12  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
166.22g/mol
Monoisotopic Mass:
166.099g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
40.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.4  
Literature
Title Journal
Hypopigmentary effects of 4-n-butylresorcinol and resveratrol in combination. Die Pharmazie 20120601
Adamantyl N-benzylbenzamide: new series of depigmentation agents with tyrosinase inhibitory activity. Bioorganic & medicinal chemistry letters 20120301
Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action. Annals of dermatology 20120201
Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. The Journal of dermatology 20100401
The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial. Annals of dermatology 20100201
Quasi-drugs developed in Japan for the prevention or treatment of hyperpigmentary disorders. International journal of molecular sciences 20100101
Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety. Bioorganic & medicinal chemistry letters 20090301
Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial. The British journal of dermatology 20070501
Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis. Biological & pharmaceutical bulletin 20051201
Properties